Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

NCT00583674 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Cancer

Interventions

DRUG: AMG 386 placebo
DRUG: AMG 386 10mg/kg
DRUG: AMG 386 3mg/kg
DRUG: Cisplatin
DRUG: Capecitabine
DRUG: Cisplatin
DRUG: Capecitabine
DRUG: Cisplatin
DRUG: Capecitabine

Sponsor

Amgen